Meckel's Diverticulum Carcinoma Is Arrested by Oxaliplatinum and Eradicated by 5-Fluorouracil in a PDX Mouse Model Indicating Candidate First-line Treatment for a Rare Cancer

In Vivo. 2023 Jul-Aug;37(4):1482-1485. doi: 10.21873/invivo.13232.

Abstract

Background/aim: Meckel's diverticulum carcinoma (MDCa) is extremely rare. It is often advanced when found, and the prognosis is poor. Effective treatment for this cancer has not yet been developed. We previously established a patient-derived xenograft (PDX) nude-mouse model of MDCa. In the present study, we investigated the efficacy of oxaliplatinum (L-OHP) and 5-fluorouracil (5-FU) on an MDCa PDX nude-mouse model.

Materials and methods: PDX mouse models of MDCa were divided into three groups (five mice per group): untreated control; L-OHP-treated; and 5-FU-treated. Tumor volumes of the three groups were compared after 2 weeks.

Results: L-OHP arrested tumor growth (p=0.038) and 5-FU apparently eradicated the tumor (p=0.007).

Conclusion: L-OHP and 5-FU are candidates for clinical first-line therapy of MDCa.

Keywords: 5-fluorouracil; Meckel’s diverticulum carcinoma; efficacy; mouse model; oxaliplatinum; patient-derived xenograft; rare cancer.

MeSH terms

  • Animals
  • Carcinoma* / drug therapy
  • Fluorouracil / pharmacology
  • Humans
  • Meckel Diverticulum* / drug therapy
  • Mice
  • Oxaliplatin / pharmacology
  • Treatment Outcome

Substances

  • Fluorouracil
  • Oxaliplatin